NCT04505839View on ClinicalTrials.gov

First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

July 30, 2020

Primary Completion Date

March 7, 2023

Study Completion Date

March 7, 2023

Conditions

Advanced Solid Tumor

Interventions

DRUG

STP1002

Oral capsule, QD

Trial Locations (3)

60208

Northwestern University, Evanston

80045

University of Colorado Denver, Denver

90033

University of Southern California, Los Angeles

Sponsors

Collaborators (1)

KCRN Research, LLC

All Listed Sponsors

collaborator

KCRN Research, LLC

INDUSTRY

lead

ST Pharm Co., Ltd.

INDUSTRY

NCT04505839 - First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors | Biotech Hunter | Biotech Hunter